Our purpose

Relieving manufacturing bottlenecks

Vision & Mission

Our ultimate goal at Exothera is to make life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for innovators to achieve successful market entry for their viral vector or RNA therapeutics

Our philosophy

The challenges of taking a viral vector or RNA-based therapy from pre-clinical development to the production of the first batch of GMP products for clinical studies can be a daunting task. The biggest challenges are a lack of access to both process development expertise and a GMP manufacturing facility with the capacity and knowledge to quickly and cost-effectively produce enough quality product for clinical trials and beyond.

Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market 

OUR HISTORY

Where we come from

1990

Belgian and Walloon ecosystem

Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.

2013

Launch of Univercells

In 2013, Univercells was created with the ambition to make biologics available and affordable to all.

2020

Creation of Exothera to relieve viral vector manufacturing bottlenecks

In March 2020, Univercells launched Exothera to support cell & gene therapy developers with process development and production of viral vectors.

With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.

The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:

 

  • Lack of expertise: there is a lack of C&GT specific expertise in this field; the CMC and manufacturing processes are highly specific. 
  • Capacity storage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months. 
  • High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient! 

2023

Launch of nucleic acids services

In January 2023, Exothera announced the launch of a new business unit, folly dedicated to the discovery, development and manufacture of DNA and RNA products.

    Vision & Mission

    Our ultimate goal at Exothera is to make life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for innovators to achieve successful market entry for their viral vector or RNA therapeutics

    Our philosophy

    The challenges of taking a viral vector or RNA-based therapy from pre-clinical development to the production of the first batch of GMP products for clinical studies can be a daunting task. The biggest challenges are a lack of access to both process development expertise and a GMP manufacturing facility with the capacity and knowledge to quickly and cost-effectively produce enough quality product for clinical trials and beyond.

    Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market 

    OUR HISTORY

    Where we come from

    1990

    Belgian and Walloon ecosystem

    Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.

    2013

    Launch of Univercells

    In 2013, Univercells was created with the ambition to make biologics available and affordable to all.

    2020

    Creation of Exothera to relieve viral vector manufacturing bottlenecks

    In March 2020, Univercells launched Exothera to support cell & gene therapy developers with process development and production of viral vectors.

    With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.

    The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:

     

    • Lack of expertise: there is a lack of C&GT specific expertise in this field; the CMC and manufacturing processes are highly specific. 
    • Capacity storage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months. 
    • High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient! 

    2023

    Launch of nucleic acids services

    In January 2023, Exothera announced the launch of a new business unit, folly dedicated to the discovery, development and manufacture of DNA and RNA products.